Global biotechnology tool company
Life Technologies Corporation
) Genetic Analysis sales are set to receive a strong boost with
its recent launch of the industry's first end-to-end sequencing
solution for whole human exome copy number variation (CNV)
This new solution combines the Ion
Reporter CNV data analysis workflow, the Ion AmpliSeq
Exome Kit and the Ion Proton System. We note that at
present, the Ion AmpliSeq Exome Kit and Ion
Proton Sequencer are used only for research.
Life Technologies enjoys a strong position in the life
sciences market. We are optimistic about the company's focus on
its diagnostics franchise, which holds potential. Given the
continuous focus on portfolio expansion, we are confident about
Life Technologies garnering higher revenues from genetic
analysis, going forward.
The Ion Torrent franchise was inducted into Life Technologies'
portfolio with the acquisition of Ion Torrent, a DNA sequencing
company, in Oct 2010. For the past few quarters, the company has
been recording robust revenue growth on the back of Ion Torrent
technology. Last year, new product introduction in this field
more than doubled the revenue of Ion Torrent franchise for the
second consecutive time.
In July, the company launched its auto imaging system EVOS FL
along with an on-stage incubator. This system enables
high-resolution, longer live, automatic cell imaging for
fluorescence microscopy and time-lapse imaging on single
In Apr 2013, two Ion AmpliSeq Community Panels, the Ion
AmpliSeq BRCA1 and BRCA2 Panel design and the Ion AmpliSeq Colon
and Lung Cancer Panel design were launched. In Feb 2013, a dozen
new products for the Ion Torrent platform were launched, based on
advancing clinical research across the world.
These new products enabled Ion Torrent semiconductor
sequencing technology to expand 1,000-fold in just 2 years and
gain a 60% market share of benchtop sequencers.
The company is satisfied with the progress made so far with
Ion Torrent technologies and expects the growth momentum to
continue. This growth was complemented by more PGM placements and
the launch of Ion Proton system in Sep 2012, in line with prior
expectations. The company is confident about yet another
significant increase in Ion Torrent franchise sales for the third
consecutive year, in keeping with the expansion.
Of late, Life Technologies has sharpened its focus on product
platforms with a string of product launches over the recent past.
The disclosure of its impending acquisition by
Thermo Fisher Scientific Inc.
) will further boost LIFE's product suite. With the overwhelming
approval of its stockholders in favor of the deal, the impending
acquisition of Life Technologies is now subject to customary
Currently, the LIFE stock carries a Zacks Rank #3 (Hold). On
the other hand,
), carrying a Zacks Rank #1 (Strong Buy) and
LeMaitre Vascular, Inc.
), carrying a Zacks Rank #2 (Buy), are worth considering.
ALERE INC (ALR): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis
LEMAITRE VASCLR (LMAT): Free Stock Analysis
THERMO FISHER (TMO): Free Stock Analysis
To read this article on Zacks.com click here.